rnai

RNA Interference – Video Animation

by Christoph on January 6, 2012

in Uncategorized

This is an amazing video animation from Nature Reviews Genetics!

This animation introduces the principles of RNAi involving small interfering RNAs (siRNAs) and microRNAs (miRNAs). It takes you on an audio-visual journey through the steps of gene expression and shows you an up-to-date view of how RNAi can silence specific mRNAs in the cytoplasm.

There is an accompanying slideshow which provides further information about RNAi and small RNAs.

High-resolution version can be found here:
http://www.nature.com/nrg/multimedia/rnai/animation/index.html

Incoming search terms for this article:

{ 0 comments }

RNAi-miRNA-siRNA-conferenceRNAi, miRNA and siRNA
27 Jun 2011 – 28 Jun 2011 – London, UK
Copthorne Tara Hotel

The conference will address:

  • RNA-based therapeutics
  • siRNA and oligoneucleotide delivery
  • The effect of pharma cuts on RNAi
  • miRNA in cardiovascular and immunology
  • Bioinformatics and computational support
  • Clinical trials and regulatory considerations
  • Epigenetics

For more information:

http://www.smi-online.co.uk/events/overview.asp?is=4&ref=3490

Incoming search terms for this article:

{ 0 comments }

Collaboration and Licensing Partners Fund Efforts in Local and Systemic Administration of Company’s Novel Delivery Systems; Marina Biotech Focuses on Clinical Pipeline and CRN Technology

BOTHELL, WA–(Marketwire – February 14, 2011) – Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today presented their integrated technology platform for the discovery of multiple oligonucleotide based therapeutics including RNAi-, microRNA- and antisense-based drugs at the BIO CEO and Investor Conference held today in New York City. J. Michael French, President and CEO of Marina Biotech, Inc. explained the strategy behind Marina Biotech’s acquisition of key intellectual property and technologies over the past year which has positioned it to provide multiple RNA-based therapeutic alternatives to pharma’s non-druggable target needs. With the Debiopharm partnership fully funding the development of the Company’s bladder cancer program using the Company’s proprietary DiLA2 delivery technology for local administration combined with licensee ProNAi funding a Phase 1 clinical trial using the Company’s proprietary Smarticles® delivery technology for systemic administration; the Company is focusing its financial resources on the Phase 1b/2a clinical trial of CEQ508 in Familial Adenomatous Polyposis (FAP) as well as development of its Conformationally Restricted Nucleotide technology (CRN) for the development of single-stranded oligonucleotide therapies.

(read the entire release… )

{ 0 comments }

NEWS RELEASE
Center Will Give San Diego’s Biomedical Community Ready Access to Nobel-Prize Winning Technology

SAN DIEGO – (October 8, 2010) - The La Jolla Institute for Allergy & Immunology will develop San Diego’s first Center for RNAi screening — a breakthrough genomics technology that will further enhance San Diego’s reputation as a national research leader and provide the local biomedical community ready access to the Nobel-Prize winning technology.

The National Institutes of Health awarded the La Jolla Institute $12.6 million to develop the Center. [click to continue…]

{ 0 comments }

Upcoming UK microRNA Conferences

by Chris on June 18, 2010

in Conferences

  • RNAi, siRNA, & miRNA – London – June 28th-29th
  • Small RNAs in Development – Welwyn Garden City – Oct 1st
  • MicroRNAs Europe 2010 – Cambridge – Nov 1st-2nd

———————————————————————————-

RNAi, siRNA, & miRNA – London – June 28th-29th

This is SMi’s fifth conference on the subject of RNAi, siRNA and miRNA.  It will build on the success of the past four years, and brings together the leading experts in industry and academia to explore the cutting edge of new therapeutics being researched and brought to the marketplace.

Taking place in London, UK, this conference will look at a wide range of issues within the RNAi arena.  It will combine a study of the latest successes in the research and development phase with presentations covering the key themes of delivery, target identification and IP issues.  (read more… )

Small RNAs in Development – Welwyn Garden City – Oct 1st

Eukaryotic gene expression is modulated at many layers of regulatory control. It is becoming apparent that differentiation and development involve the action of numerous regulatory non-protein coding RNAs (ncRNAs). This meeting will focus on the discovery and characterization of ncRNAs in the context of embryogenesis and organismal development, highlighting recent technological advances for high-throughput functional genomics.  (read more… )

MicroRNAs Europe 2010 – Cambridge – Nov 1st-2nd

MicroRNAs: Biology to Development and Disease – located at the Peterhouse College, the oldest College of the University of Cambridge, founded in 1284 and an institution dedicated to education and research. (read more… )

Incoming search terms for this article:

{ 0 comments }

Number of Companies working on RNAi Based Therapeutics is Exploding!

November 3, 2009

AiRNA Pharmaceuticals Allergan Alnylam Pharmaceuticals Benitec BioCandell Therapeutics Calando Pharmaceuticals Cenix BioScience Cequent Pharmaceuticals Copernicus Therapeutics Dicerna Pharmaceuticals Expression Genetics Corporation General Research Laboratory Intradigm Corporation MDRNA Mirna Therapeutics MiRagen Therapeutics Nitto Denko Technical Corp Opko Health Oxford BioMedica Polyplus Transfection Quark Pharmaceuticals Regulus Therapeutics RXi Therapeutics Santaris Pharma Senesco Technologies Silence Therapeutics Siranoamics siRNAsense […]

Read the full article →